ProfitQuotes.com
symbol lookup  commodity list
Bookmark This Page
Friday's ETF with Unusual Volume: RSPU

Fri, 03 May 16:24:07 GMT
S&P 500 Analyst Moves: CTRA

Fri, 03 May 16:12:25 GMT
Portfolio Channel
Free Energy Dividend Stock Report
Free Dividend Report - Top Ranked Stocks
Free Dividend Paying Gold/Metals Stocks Report
Get a quote box (like the one below) for your site!
ProfitQuotes.com Commodities Quotes
commodity quotes list
energy quotes  gold quotes
uranium stocks  
solar power stocks

wind power stocks

Industry focus:

advertising stocks,
space stocks,
aerospace stock,
aerospace sector,
list of aerospace companies,
largest chemical companies,
chemical stock,
chemical news,
best agriculture stocks,
ag stocks,
chinese agriculture stocks,
top agriculture companies,
agriculture stocks,
agricultural stocks,
agricultural stock,
stocks agriculture,
agriculture markets,
agriculture index,
agriculture industries,
agricultural investment,
agriculture investment,
agricultural industry,
farm stock,
airline stock symbols,
airline stock prices,
airline stock,
airlines stock,
clothing stock,
fashion stocks,
publicly traded fashion companies,
clothing company stocks,
apparel stock,
apparel companies,
application software stocks,
asset management stocks,
auto stocks,
auto industry stocks,
chinese auto stocks,
auto stock prices,
automotive stock,
auto parts stocks,
community bank stocks,
regional bank stocks,
canadian bank stocks,
banking stock,
national bank stocks,
commercial bank stock,
banks stock,
bank stock quote,
bank stocks,
banking industry,
alcohol stocks,
beverage stock,
global wine stocks,
wine stocks,
liquor stock,
biotech stocks list,
biotechnology investing,
public biotech companies,
top biotech stocks,
nanotechnology stock,
largest biotech companies,
biotechnology stock,
biotech investing,
investing in biotech,
best biotech companies,
bio stocks,
biotech sector,
biotechnology investment,
biopharma companies,
new biotech companies,
biotech investment,
biotechnology industries,
nanotech stocks,
biotech stocks,
biotechnology articles,
biotechnology news,
business stocks,
service stocks,
chemical companies,
chemical industries,
chemical industry,
chemical company,
chemicals company,
cigarette stock,
cigarette company stocks,
cigarette stock symbols,
tobacco company stocks,
tobacco stock,
cigar stocks,
communications stocks,
communication stock,
computer peripherals companies,
computer peripherals,
computers stocks,
computer stock,
computer web,
internet stocks,
construction stocks,
machinery stocks,
builders stocks,
building stocks,
consumer goods stocks,
consumer services stocks,
consumer services companies,
lending stocks,
mortgage banking,
lending companies,
mortgage bankers,
loan services,
mortgage services,
mortgage bank,
loan bank,
defense stocks,
defensive stock,
department store stocks,
diagnostic company,
diagnostic companies,
pharmaceuticals stocks,
drug stocks,
drug company stocks,
pharma stock,
education stocks,
college stock,
electric utility stocks,
electric company stocks,
electric utilities stocks,
utility stocks,
utilities stocks,
power equipment companies,
electrical supply companies,
electronic stocks,
entertainment stock,
movie stocks,
movies companies,
movie company,
cefs,
open ended and closed ended mutual funds,
closed ended investment,
closed ended fund,
bonds fund,
closed end,
food stock,
game stock,
gambling stocks,
casino stocks,
gaming stocks list,
gaming stocks,
gas utility companies,
gas company stocks,
construction industries,
builders contractors,
construction services,
construction industry,
grocery store stocks,
supermarket stock,
drug store stocks,
home stocks,
furniture stock,
home improvement stocks,
medical company stocks,
top medical stocks,
medical stock,
hospital stock,
medical supply stocks,
medical technology stocks,
medical device stocks,
medical equipment stocks,
copper mining,
palladium mining stocks,
mining metals,
mining,
mining news,
gold exploration,
mining share price,
lithium mines,
mining industries,
international mining companies,
mining information,
molybdenum mining companies,
nickel mining companies,
metals and mining stocks,
gold and silver mining stocks,
copper mining companies,
rare earth mining companies,
rare metals stocks,
rare earth stocks,
metals stocks,
welding stock,
nonprecious metals,
non metallic mining,
office supplies companies,
office supply companies,
oil services stocks,
oil pipeline stocks,
gas pipeline stocks,
gas pipeline companies,
pipeline companies,
natural gas pipeline companies,
oil services companies,
oil field services,
oil service stocks,
natural gas pipelines,
oilfield service companies,
oil and gas pipeline companies,
oil gas pipeline,
oil exploration stocks,
oil exploration sector,
oil exploration companies,
oil drilling stocks,
oil drilling companies,
oil production companies,
china oil companies,
brazil oil companies,
china oil stocks,
brazil oil stocks,
oil companies,
oil stocks,
oil drilling,
oil exploration,
offshore oil drilling companies,
list of oil drilling companies,
oil and gas exploration,
oil and gas drilling,
oil and gas stocks,
oil and gas drilling companies,
oil refining companies,
oil marketing companies,
oil refining stocks,
oil refining sector,
oil refinery companies,
oil refinery stocks,
major oil companies,
oil sector,
oil refinery,
oil refinery company,
oil company,
oil marketing company,
oil refining company,
oil refining industry,
major oil companies list,
oil and gas companies,
crude oil stocks,
packaging companies,
container companies,
packaging stocks,
packaging sector,
container sector,
pulp stocks,
paper stocks,
timber stocks,
pulp companies,
paper companies,
timber companies,
timber trusts,
cardboard companies,
paper sector,
timber sector,
paper companies list,
silver mining companies,
gold mining companies,
gold mining sector,
precious metal stocks,
mining companies,
exploration sector,
mining sector,
exploration stocks,
mining stocks,
silver stocks,
gold stocks,
gold mining stocks,
silver mining stocks,
silver mining company,
canadian mining companies,
gold mining,
gold mining company,
mining company,
list of mining companies,
gold stocks list,
largest gold mining companies,
silver mining,
printing companies,
printing stocks,
printing sector,
newspaper stocks,
newspaper sector,
newspaper companies,
publishing stocks,
publishing sector,
publishing companies,
digital media companies,
digital media stocks,
digital media sector,
book publishing companies,
digital media company,
publishing company,
railroad stocks,
railroad sector,
railroad companies,
railroad company,
railroad investment,
major railroad companies,
real estate companies,
real estate stock,
real estate public companies,
real estate investing,
real estate investments,
real estate sector,
commercial real estate investing,
real estate investment firms,
real estate investing guide,
REITs,
real estate investment trust,
REIT sector,
REIT stocks,
REITs sector,
REITs stock,
public REITs,
real estate investment trusts,
real estate investment trust companies,
real estate investment trusts REITs,
real estate investment companies,
real estate investment company,
real estate investment trust REIT,
rubber stocks,
plastic stocks,
rubber companies,
plastic companies,
rubber sector,
plastic sector,
plastic manufacturing companies,
rubber company,
plastic company,
semiconductor stocks,
semiconductor investments,
semi stocks,
semiconductor companies,
semiconductor sector,
shipping stocks,
dry bulk stocks,
container stocks,
dry bulk shipping,
dry bulk shipping companies,
tanker stocks,
shipping companies,
shipping sector,
specialty retail,
retail stocks,
retail investing,
retail store stocks,
consumer stocks,
consumer investment,
retail companies,
retail sector,
sports stocks,
sports investing,
sporting goods stocks,
sports investments,
sporting goods companies,
sporting goods sector,
stock message boards,
television stocks,
television investment,
radio stocks,
radio invest,
media stocks,
media invest,
media investment,
media investing,
television companies,
television sector,
radio sector,
radio companies,
media companies,
media sector,
textile stocks,
apparel stocks,
textile investment,
textile companies,
textile sector,
apparel sector,
freight investment,
transportation investment,
truck investment ,
freight stocks,
transportation stocks,
trucking stocks,
trucking companies,
trucking sector,
waste management stocks,
waste stocks,
recycling stocks,
waste investment,
waste companies,
waste sector,
water stocks,
water utilities,
water investing,
water investment,
water companies,
water sector

Home Oil & Gas Electricity Metals Treasuries Stocks My Portfolios Forex
News - Full Story
 Related Quotes
 Amedisys Inc  92.08   0.35  0.38%
 Enter Symbols: 
Amedisys Reports First Quarter 2024 Financial Results

BATON ROUGE, La., April 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2024.

Three-Month Periods Ended March 31, 2024 and 2023

  • Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023. Prior year included $15.0 million of net service revenue from our personal care business which was divested on March 31, 2023.
  • Net income attributable to Amedisys, Inc. of $14.4 million, which is inclusive of merger-related expenses totaling $20.7 million ($19.8 million, net of tax), compared to $25.2 million in 2023.
  • Net income attributable to Amedisys, Inc. per diluted share of $0.44 compared to $0.77 in 2023.

Adjusted Quarterly Results*

  • Adjusted EBITDA of $59.9 million compared to $57.8 million in 2023.
  • Adjusted net income attributable to Amedisys, Inc. of $33.9 million compared to $32.7 million in 2023.
  • Adjusted net income attributable to Amedisys, Inc. per diluted share of $1.03 compared to $1.00 in 2023.

* See pages 11 - 12 for the definition and reconciliations of non-GAAP financial measures to GAAP measures.

The supplemental slides provided in connection with the first quarter 2024 earnings release can be found on the Investor Relations page of our website. In light of the pending merger of the Company with UnitedHealth Group Incorporated, Amedisys will not conduct a quarterly earnings call to discuss the first quarter results.

Non-GAAP Financial Measures

This press release includes reconciliations of the most comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the U.S. ("GAAP") to non-GAAP financial measures. The non-GAAP financial measures as defined under SEC rules are as follows: (1) adjusted EBITDA, defined as net income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items; (2) adjusted net income attributable to Amedisys, Inc., defined as net income attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items; and (3) adjusted net income attributable to Amedisys, Inc. per diluted share, defined as net income attributable to Amedisys, Inc. common stockholders per diluted share calculated in accordance with GAAP excluding certain items. Management believes that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, are useful gauges of our current performance and are also included in internal management reporting. These non-GAAP financial measures should be considered in addition to, and not more meaningful than or as an alternative to, the GAAP financial measures presented in this earnings release and the company's financial statements. Non-GAAP measures as presented herein may not be comparable to similarly titled measures reported by other companies since not all companies calculate these non-GAAP measures consistently.

Additional Information

Amedisys, Inc. (the "Company") is a leading healthcare at home company delivering personalized home health, hospice and high acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is in-patient hospital, palliative and skilled nursing facility ("SNF") care in their homes, home-based recovery and rehabilitation after an operation or injury, care focused on empowering our patients to manage a chronic disease or hospice care at the end of life. More than 3,000 hospitals and 110,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 18,700 employees in 520 care centers within 37 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 469,000 patients every year. For more information about the Company, please visit: www.amedisys.com.

We use our website as a channel of distribution for important company information. Important information, including press releases, investor presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled "Investors" on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website.

Forward-Looking Statements

When included in this press release, words like "believes," "belief," "expects," "strategy," "plans," "anticipates," "intends," "projects," "estimates," "may," "might," "will," "could," "would," "should" and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to, the following: disruption from the proposed merger with UnitedHealth Group with patient, payor, provider, referral source, supplier or management and employee relationships; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement with UnitedHealth Group or the inability to complete the proposed transaction on the anticipated terms and timetable; the risk that necessary regulatory approvals for the proposed merger with UnitedHealth Group are delayed, are not obtained or are obtained subject to conditions that are not anticipated; the failure of the conditions to the proposed merger to be satisfied; the costs related to the proposed merger; the diversion of management time on merger-related issues; the risk that termination fees may be payable by the Company in the event that the merger agreement is terminated under certain circumstances; reputational risk related to the proposed merger; the risk of litigation or regulatory action related to the proposed merger; changes in Medicare and other medical payment levels; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; changes in the episodic versus non-episodic mix of our payors, the case mix of our patients and payment methodologies; staffing shortages driven by the competitive labor market; our ability to attract and retain qualified personnel; competition in the healthcare industry; our ability to maintain or establish new patient referral sources; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; changes in estimates and judgments associated with critical accounting policies; our ability to consistently provide high-quality care; our ability to keep our patients and employees safe; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural or man-made disasters, climate change or acts of terrorism, widespread protests or civil unrest; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; our ability to integrate, manage and keep our information systems secure; the impact of inflation; and changes in laws or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

Contact: Investor Contact: Media Contact:
Amedisys, Inc. Amedisys, Inc.
Nick Muscato Kendra Kimmons
Chief Strategy Officer Vice President, Marketing & Communications
(615) 928- 5452 (225) 299-3720
IR@amedisys.comkendra.kimmons@amedisys.com


AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED INCOME STATEMENTS
(Amounts in thousands, except per share data)
(Unaudited)
For the Three-Month
Periods Ended March 31,
2024 2023
Net service revenue$571,414 $556,389
Operating expenses:
Cost of service, inclusive of depreciation 321,537 315,010
General and administrative expenses:
Salaries and benefits 127,946 126,339
Non-cash compensation 7,433 3,273
Merger-related expenses 20,667 720
Depreciation and amortization 4,271 4,443
Other 57,941 64,225
Total operating expenses 539,795 514,010
Operating income 31,619 42,379
Other income (expense):
Interest income 1,727 406
Interest expense (8,119) (7,517)
Equity in earnings from equity method investments 910 123
Miscellaneous, net 1,090 (682)
Total other expense, net (4,392) (7,670)
Income before income taxes 27,227 34,709
Income tax expense (12,633) (9,800)
Net income 14,594 24,909
Net (income) loss attributable to noncontrolling interests (194) 337
Net income attributable to Amedisys, Inc.$14,400 $25,246
Basic earnings per common share:
Net income attributable to Amedisys, Inc. common stockholders$0.44 $0.78
Weighted average shares outstanding 32,670 32,558
Diluted earnings per common share:
Net income attributable to Amedisys, Inc. common stockholders$0.44 $0.77
Weighted average shares outstanding 32,979 32,643


AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except share data)
March 31, 2024
(unaudited)
December 31,
2023
ASSETS
Current assets:
Cash and cash equivalents$108,234 $126,450
Restricted cash 12,470 12,413
Patient accounts receivable 359,359 313,373
Prepaid expenses 20,332 14,639
Other current assets 26,053 30,060
Total current assets 526,448 496,935
Property and equipment, net of accumulated depreciation of $96,056 and $92,422 42,684 41,845
Operating lease right of use assets 88,425 88,939
Goodwill 1,244,679 1,244,679
Intangible assets, net of accumulated amortization of $15,128 and $14,008 101,778 102,675
Other assets 85,857 85,097
Total assets$2,089,871 $2,060,170
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable$36,249 $28,237
Payroll and employee benefits 131,631 136,835
Accrued expenses 147,464 140,049
Termination fee paid by UnitedHealth Group 106,000 106,000
Current portion of long-term obligations 37,232 36,314
Current portion of operating lease liabilities 26,284 26,286
Total current liabilities 484,860 473,721
Long-term obligations, less current portion 356,080 361,862
Operating lease liabilities, less current portion 62,220 62,751
Deferred income tax liabilities 43,229 40,635
Other long-term obligations 828 1,418
Total liabilities 947,217 940,387
Equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding
Common stock, $0.001 par value, 60,000,000 shares authorized; 38,146,546 and 38,131,478 shares issued; 32,676,115 and 32,667,631 shares outstanding 38 38
Additional paid-in capital 795,063 787,177
Treasury stock, at cost, 5,470,431 and 5,463,847 shares of common stock (469,243) (468,626)
Retained earnings 762,325 747,925
Total Amedisys, Inc. stockholders' equity 1,088,183 1,066,514
Noncontrolling interests 54,471 53,269
Total equity 1,142,654 1,119,783
Total liabilities and equity$2,089,871 $2,060,170


AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS AND DAYS REVENUE OUTSTANDING
(Amounts in thousands, except statistical information)
(Unaudited)
For the Three-Month
Periods Ended March 31,
2024 2023
Cash Flows from Operating Activities:
Net income$14,594 $24,909
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Depreciation and amortization (inclusive of depreciation included in cost of service) 6,138 5,694
Non-cash compensation 7,886 3,273
Amortization and impairment of operating lease right of use assets 8,566 8,622
Loss (gain) on disposal of property and equipment 4 (70)
Loss on personal care divestiture 2,186
Deferred income taxes 2,594 2,772
Equity in earnings from equity method investments (910) (123)
Amortization of deferred debt issuance costs 248 248
Return on equity method investments 170 1,787
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable (46,806) (7,476)
Other current assets (1,696) (4,128)
Operating lease right of use assets (1,042) (918)
Other assets 155 (111)
Accounts payable 8,652 (3,457)
Accrued expenses 3,029 741
Other long-term obligations (591) (28)
Operating lease liabilities (7,532) (7,960)
Net cash (used in) provided by operating activities (6,541) 25,961
Cash Flows from Investing Activities:
Proceeds from the sale of deferred compensation plan assets 21 19
Purchases of property and equipment (2,670) (1,350)
Investments in technology assets (223) (210)
Investment in equity method investee (196)
Proceeds from personal care divestiture 47,787
Acquisitions of businesses, net of cash acquired (350)
Net cash (used in) provided by investing activities (3,068) 45,896
Cash Flows from Financing Activities:
Proceeds from issuance of stock under employee stock purchase plan 816
Shares withheld to pay taxes on non-cash compensation (617) (1,308)
Noncontrolling interest contributions 1,764
Noncontrolling interest distributions (756) (285)
Purchase of noncontrolling interest (800)
Proceeds from borrowings under revolving line of credit 8,000
Repayments of borrowings under revolving line of credit (8,000)
Principal payments of long-term obligations (8,941) (55,313)
Net cash used in financing activities (8,550) (56,890)
Net (decrease) increase in cash, cash equivalents and restricted cash (18,159) 14,967
Cash, cash equivalents and restricted cash at beginning of period 138,863 54,133
Cash, cash equivalents and restricted cash at end of period$120,704 $69,100
For the Three-Month
Periods Ended March 31,
2024 2023
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest$8,188 $6,654
Cash paid for income taxes, net of refunds received$828 $352
Cash paid for operating lease liabilities$8,574 $8,878
Cash paid for finance lease liabilities$2,236 $2,457
Supplemental Disclosures of Non-Cash Activity:
Right of use assets obtained in exchange for operating lease liabilities$7,173 $7,083
Right of use assets obtained in exchange for finance lease liabilities$4,326 $20,790
Reductions to right of use assets resulting from reductions to operating lease liabilities$168 $141
Reductions to right of use assets resulting from reductions to finance lease liabilities$496 $369
Days revenue outstanding (1) 54.1 46.3
(1) Our calculation of days revenue outstanding at March 31, 2024 and 2023 is derived by dividing our ending patient accounts receivable by our average daily patient revenue for the three-month periods ended March 31, 2024 and 2023, respectively.


AMEDISYS, INC. AND SUBSIDIARIES
SEGMENT INFORMATION
(Amounts in millions, except statistical information)
(Unaudited)
Segment Information - Home Health
For the Three-Month Periods
Ended March 31,
2024 2023
Financial Information (in millions):
Medicare$215.8 $215.4
Non-Medicare 148.2 127.9
Net service revenue 364.0 343.3
Cost of service, inclusive of depreciation 210.4 197.0
Gross margin 153.6 146.3
General and administrative expenses 91.0 89.1
Depreciation and amortization 1.8 1.1
Operating income$60.8 $56.1
Same Store Growth(1):
Medicare revenue % (7%)
Non-Medicare revenue 16% 12%
Total admissions 10% 8%
Total volume(2) 8% 5%
Key Statistical Data - Total(3):
Admissions 112,215 101,963
Recertifications 43,961 43,325
Total volume 156,176 145,288
Medicare completed episodes 72,998 73,563
Average Medicare revenue per completed episode(4)$2,998 $2,974
Medicare visits per completed episode(5) 11.9 12.4
Visiting clinician cost per visit$105.38 $100.00
Clinical manager cost per visit 11.99 10.97
Total cost per visit$117.37 $110.97
Visits 1,792,629 1,775,206
(1) Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
(2) Total volume includes all admissions and recertifications.
(3) Total includes acquisitions, startups and de novos.
(4) Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care.
(5) Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.

Segment Information - Hospice

For the Three-Month Periods
Ended March 31,
2024 2023
Financial Information (in millions):
Medicare$190.0 $182.7
Non-Medicare 11.0 10.7
Net service revenue 201.0 193.4
Cost of service, inclusive of depreciation 105.3 101.4
Gross margin 95.7 92.0
General and administrative expenses 48.1 47.9
Depreciation and amortization 0.7 0.6
Operating income$46.9 $43.5
Same Store Growth(1):
Medicare revenue 4% %
Hospice admissions (3%) (5%)
Average daily census % (1%)
Key Statistical Data - Total(2):
Hospice admissions 12,657 12,998
Average daily census 12,767 12,730
Revenue per day, net$173.04 $168.83
Cost of service per day$90.64 $88.21
Average discharge length of stay 92 90
(1) Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
(2) Total includes acquisitions and de novos.

Segment Information - Personal Care (1)

For the Three-Month Periods
Ended March 31,
2024 2023
Financial Information (in millions):
Medicare$ $
Non-Medicare 15.0
Net service revenue 15.0
Cost of service, inclusive of depreciation 11.1
Gross margin 3.9
General and administrative expenses 2.3
Depreciation and amortization
Operating income$ $1.6
Key Statistical Data - Total:
Billable hours 440,464
Clients served 7,892
Shifts 191,379
Revenue per hour$ $33.97
Revenue per shift$ $78.19
Hours per shift 2.3
(1) We completed the sale of our personal care business on March 31, 2023.

Segment Information - High Acuity Care

For the Three-Month Periods
Ended March 31,
2024 2023
Financial Information (in millions):
Medicare$ $
Non-Medicare 6.4 4.7
Net service revenue 6.4 4.7
Cost of service, inclusive of depreciation 5.8 5.5
Gross margin 0.6 (0.8)
General and administrative expenses 5.9 4.4
Depreciation and amortization 0.9 0.8
Operating loss$(6.2) $(6.0)
Key Statistical Data - Total:
Full risk admissions 139 158
Limited risk admissions 622 459
Total admissions 761 617
Total admissions growth 23% 85%
Full risk revenue per episode$10,073 $11,343
Limited risk revenue per episode$6,780 $5,711
Number of admitting joint ventures 9 9

Segment Information - Corporate

For the Three-Month Periods
Ended March 31,
2024 2023
Financial Information (in millions):
General and administrative expenses$69.0 $50.9
Depreciation and amortization 0.9 1.9
Total operating expenses$69.9 $52.8


AMEDISYS, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO GAAP MEASURES
(Amounts in thousands)
(Unaudited)
Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("Adjusted EBITDA") Reconciliation:
For the Three-Month Periods
Ended March 31,
2024 2023
Net income attributable to Amedisys, Inc.$14,400 $25,246
Add:
Income tax expense 12,633 9,800
Interest expense, net 6,392 7,111
Depreciation and amortization 6,138 5,694
Certain items(1) 20,296 9,987
Adjusted EBITDA(2)(5)$59,859 $57,838

Adjusted Net Income Attributable to Amedisys, Inc Reconciliation:

For the Three-Month Periods
Ended March 31,
2024 2023
Net income attributable to Amedisys, Inc.$14,400 $25,246
Add:
Certain items(1) 19,548 7,489
Adjusted net income attributable to Amedisys, Inc.(3)(5)$33,948 $32,735

Adjusted Net Income Attributable to Amedisys, Inc. per Diluted Share Reconciliation:

For the Three-Month Periods
Ended March 31,
2024 2023
Net income attributable to Amedisys, Inc. common stockholders per diluted share$0.44 $0.77
Add:
Certain items(1) 0.59 0.23
Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share(4)(5)$1.03 $1.00
(1) The following details the certain items for the three-month periods ended March 31, 2024 and 2023:

Certain Items (in thousands):

For the Three-Month Periods
Ended March 31,
2024 2023
(Income) Expense (Income) Expense
Certain Items Impacting Cost of Service, Inclusive of Depreciation:
Clinical optimization and reorganization costs$ $114
Certain Items Impacting General and Administrative Expenses:
Acquisition and integration costs 1,667
CEO transition 750
Merger-related expenses 20,667 720
Clinical optimization and reorganization costs 3,170
Personal care divestiture 514
Certain Items Impacting Total Other Income (Expense):
Other (income) expense, net (371) 3,052
Total$20,296 $9,987
Net of tax$19,548 $7,489
Diluted EPS$0.59 $0.23
(2) Adjusted EBITDA is defined as net income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items as described in footnote 1.
(3) Adjusted net income attributable to Amedisys, Inc. is defined as net income attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items as described in footnote 1.
(4) Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share is defined as diluted income per share calculated in accordance with GAAP excluding the earnings per share effect of certain items as described in footnote 1.
(5) Adjusted EBITDA, adjusted net income attributable to Amedisys, Inc. and adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share should not be considered as an alternative to, or more meaningful than, income before income taxes or other measures calculated in accordance with GAAP. These calculations may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate these non-GAAP financial measures in the same manner.

Primary Logo

<  back


TickerTech.com Private-label branded pages powered by TickerTech.com. Copyright © 2024 Ticker Technologies, All Rights Reserved. Quote data is at least 20 minutes delayed. NYMEX/COMEX data is at least 30 minutes delayed. Please read other important disclaimer information.
"As long as people will accept crap, it will be financially profitable to dispense it." - Dick Cavett
Google
 

© Ticker Technologies, all rights reserved. Profitquotes.com is wholly owned by Ticker Technologies and serves to demonstrate the company's products to prospective clients. All quotes are in US Eastern Time (EST) and delayed at least 15 minutes. NYMEX/COMEX data delayed at least 30 minutes. Data is presented for informational purposes only and not intended for investment purposes. Nothing on this site should be considered advice, opinions, recommendations, or endorsements from ProfitQuotes.com or TTI Group. Full Disclaimer.